BlackRock Discloses Significant Stake in Day One Biopharmaceuticals
Ticker: DAWN · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1845337
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, pharmaceuticals
TL;DR
**BlackRock just revealed a big, passive stake in Day One Bio, signaling institutional confidence.**
AI Summary
BlackRock Inc., a major investment firm, reported on January 29, 2024, that it holds a significant stake in Day One Biopharmaceuticals, Inc. as of December 31, 2023. This filing indicates BlackRock's passive ownership of Day One Biopharmaceuticals' Common Stock, signaling their confidence in the pharmaceutical company. For investors, this means a large, influential institutional investor sees value in Day One Biopharmaceuticals, which can be a positive signal for the stock's stability and future prospects.
Why It Matters
This filing shows a major institutional investor, BlackRock, has a substantial, passive stake in Day One Biopharmaceuticals, which can lend credibility and stability to the stock.
Risk Assessment
Risk Level: low — The filing indicates a passive investment by a large institution, which generally reduces risk by showing institutional backing.
Analyst Insight
A smart investor would view BlackRock's passive stake as a vote of confidence, potentially indicating stability and long-term value in Day One Biopharmaceuticals, and might consider further research into the company's fundamentals.
Key Players & Entities
- BlackRock Inc. (company) — the investment firm filing the SC 13G
- Day One Biopharmaceuticals, Inc. (company) — the subject company whose stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 29, 2024 (date) — the filing date of the SC 13G
Forward-Looking Statements
- BlackRock will maintain its passive stake in Day One Biopharmaceuticals for the foreseeable future. (BlackRock Inc.) — high confidence, target: 2025-01-29
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically filed under Rule 13d-1(b) as indicated by the 'X' in the appropriate box.
Who is the reporting person in this SC 13G filing?
The reporting person is BlackRock Inc., a security brokers, dealers & flotation company based in New York, NY.
Which company's securities are being reported on in this filing?
The securities being reported on belong to Day One Biopharmaceuticals, Inc., a pharmaceutical preparations company based in Brisbane, CA.
What is the CUSIP number for the class of securities mentioned?
The CUSIP number for the Common Stock of Day One Biopharmaceuticals, Inc. is 23954D109.
What was the 'Date of Event Which Requires Filing of this Statement'?
The date of the event which required the filing of this statement was December 31, 2023.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 regarding Day One Biopharmaceuticals, Inc. (DAWN).